Number of shares and votes in Calliditas Therapeutics

Rhea-AI Summary

Calliditas Therapeutics AB has updated its share structure as of July 29, 2022. The company has issued 51,399 ordinary shares related to its long-term incentive program for board members and converted 5,908,018 class C-shares into ordinary shares, establishing its at-the-market program. Following these changes, the total number of shares and votes stands at 59,157,587. Calliditas focuses on developing treatments for orphan diseases, with its lead product Nefecon receiving FDA accelerated approval.

Positive

• Completion of share conversion strengthens liquidity with 59,157,587 total shares.
• Nefecon (TARPEYO™) continues to gain traction in FDA approvals, enhancing market position.

Negative

• None.

STOCKHOLM, July 29, 2022 /PRNewswire/ -- During July, Calliditas Therapeutics AB (publ) has issued 51,399 ordinary shares as part of the company's long-term incentive program for certain members of the board of directors issued in 2019, Board LTIP 2019, and converted 5,908,018 class C-shares to 5,908,018 ordinary shares as part of the establishment of the company's at-the-market program. Thus, as of July 29, 2022, the number of shares and votes in the company amounts to 59,157,587 shares and 59,157,587 votes.

For further information, please contact:
Mikael Widell, Investor relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com 

The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 CEST on July 29, 2022.

About Calliditas

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Calliditas' lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO™ and conditional marketing authorization by the European Commission under the trade name KINPEYGO®. Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3608053

The following files are available for download:

https://mb.cision.com/Main/16574/3608053/1610015.pdf

Number of shares and votes July 2022 (Eng)

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301596031.html

SOURCE Calliditas Therapeutics

FAQ

What recent share changes occurred for Calliditas Therapeutics on July 29, 2022?

On July 29, 2022, Calliditas Therapeutics issued 51,399 ordinary shares and converted 5,908,018 class C-shares to ordinary shares, updating the total shares to 59,157,587.

What is the significance of the share conversion for shareholders?

The conversion of class C-shares to ordinary shares enhances liquidity and maintains the total share count, which is crucial for shareholder value.

How has Calliditas Therapeutics performed in the market recently?

Calliditas continues to enhance its market position with the accelerated approval of its lead product, Nefecon, under the trade name TARPEYO™.

What is the ticker symbol for Calliditas Therapeutics on the Nasdaq?

The ticker symbol for Calliditas Therapeutics is CALT.